- Home
- L vs ROIV Comparison
L vs ROIV Comparison
Compare L & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | L | ROIV |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0B | 20.7B |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | L | ROIV |
|---|---|---|
| Price | $107.09 | $26.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $27.56 |
| AVG Volume (30 Days) | 552.1K | ★ 4.5M |
| Earning Date | 05-04-2026 | 02-06-2026 |
| Dividend Yield | ★ 0.24% | N/A |
| EPS Growth | ★ 24.34 | N/A |
| EPS | ★ 7.97 | N/A |
| Revenue | ★ $18,454,000,000.00 | $29,053,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $594.84 |
| P/E Ratio | $13.25 | ★ N/A |
| Revenue Growth | ★ 5.39 | N/A |
| 52 Week Low | $78.98 | $8.73 |
| 52 Week High | $114.90 | $30.33 |
Technical Indicators
Market Signals| Indicator | L | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 44.83 | 45.05 |
| Support Level | $101.11 | $26.94 |
| Resistance Level | $108.12 | $27.94 |
| Average True Range (ATR) | 1.82 | 0.90 |
| MACD | -0.44 | -0.39 |
| Stochastic Oscillator | 37.65 | 9.63 |
Price Performance
Historical ComparisonAbout L Loews Corporation
Loews Corp is a holding company along with its subsidiary engaged in commercial property and casualty insurance, transportation and storage of natural gas and natural gas liquids, operation of a chain of hotels, and also in the manufacture of rigid plastic packaging solutions. It has four reportable segments comprised of three individual consolidated operating subsidiaries, CNA Financial Corporation, Boardwalk Pipeline Partners, LP and Loews Hotels Holding Corporation; and the Corporate segment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.